In 2022, during an extensive prioritisation exercise with National Malaria Programmes in the Asia Pacific region, the APMEN Vivax Working Group found that NMPs wanted to better understand the safety of shorter course primaquine for vivax malaria. This reflects the latest WHO recommendations which identified an evidence gap on the safety of shorter course primaquine. Studies and analyses are underway to try to bridge this gap. This TechTalk webinar discussed recent research and meta-analyses on primaquine safety and identify what additional evidence is required. |

Moderator - 

• Dr Neena Valecha, Chair of APMEN Vivax Working Group, and Former Regional Advisor, Malaria at WHO Regional Office of South-East Asia | 

Panellists - 

• Dr Rob Commons, Senior Research Fellow, Menzies School of Health Research, Australia;
• Dr Ayodhia Pitaloka Pasaribu, Professor, Department of Child Health, Medical Faculty, Universitas Sumatera Utara, Indonesia;
• Dr Lyndes Wini, Head of the Case Management Unit, Vector Borne Diseases Control Division, Ministry of Health & Medical Services, Solomon Islands; and
• Dr Peter Ehizibue Olumese, Medical Officer, Malaria Case Management at Global Malaria Programme, WHO Geneva.